Akèy › Sistèm Imunitè ak Twoub › Washington
Etid klinik pou Sistèm Imunitè ak Twoub nan Washington
7 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- University of Washingto, Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- ak 18 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 17, 2026 · NCT04242095METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
- University of Washington Medicine Diabetes Institute (UWMDI), Seattle
Ap rekriteFaz 2
Laj 18 a 69 · Tout sèks · Mizajou Sep 15, 2026 · NCT07699380A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- University of Washingto, Seattle
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06948318A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 7, Burien
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Aug 12, 2026 · NCT07037901CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- University of Washington Medical Center, Seattle
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.